France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

merck sante - tégafur - gélule - 100 mg - composition pour une gélule > tégafur : 100 mg > uracile : 224 mg - classification agents antinéoplasiques, antimetabolites, analogues des pyrimidines.

Union européenne - français - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil de chlorhydrate de - néoplasmes colorectaux - agents antinéoplasiques - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Union européenne - français - EMA (European Medicines Agency)

nordic group b.v. - tegafur, gimeracil, l'otéracil - néoplasmes stomacaux - agents antinéoplasiques - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

servier (suisse) sa - trifluridinum, tipiracilum - comprimés pelliculés - trifluridinum 15 mg, tipiracilum 6.14 mg ut tipiracili hydrochloridum, lactosum monohydricum 90.735 mg, amylum pregelificatum, acidum stearicum, pellicule: hypromellosum, macrogolum 8000, e 171, magnesii stearas, encre: lacca, e 172 (rubrum), e 172 (flavum), e 171, e 132, cera carnauba, talcum, pro compresso obducto. - cancer colorectal métastatique, cancer gastrique métastatique - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

servier (suisse) sa - trifluridinum, tipiracilum - comprimés pelliculés - trifluridinum 20 mg, tipiracilum 8.19 mg ut tipiracili hydrochloridum, lactosum monohydricum 120.980 mg, amylum pregelificatum, acidum stearicum, pellicule: hypromellosum, macrogolum 8000, e 171, e 172 (rubrum), magnesii stearas, encre: lacca, e 172 (rubrum), e 172 (flavum), e 171, e 132, cera carnauba, talcum, pro compresso obducto. - cancer colorectal métastatique, cancer gastrique métastatique - synthetika

Canada - français - Health Canada

cipher pharmaceuticals inc - fluorouracil; acide salicylique - solution - 0.5%; 10% - fluorouracil 0.5%; acide salicylique 10% - antineoplastic agents

Canada - français - Health Canada

taiho pharma canada, inc. - trifluridine; tipiracil (chlorhydrate de tipiracil) - comprimé - 15mg; 6.14mg - trifluridine 15mg; tipiracil (chlorhydrate de tipiracil) 6.14mg - antineoplastic agents

Canada - français - Health Canada

taiho pharma canada, inc. - trifluridine; tipiracil (chlorhydrate de tipiracil) - comprimé - 20mg; 8.19mg - trifluridine 20mg; tipiracil (chlorhydrate de tipiracil) 8.19mg - antineoplastic agents

Canada - français - Health Canada

otsuka pharmaceutical co ltd - dÉcitabine; cédazuridine - comprimé - 35mg; 100mg - dÉcitabine 35mg; cédazuridine 100mg - antineoplastic agents

Union européenne - français - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leucémie, myéloïde - agents antinéoplasiques - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.